Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche, Biogen Idec To Terminate Ocrelizumab Treatment
Ocrelizumab is also being evaluated for relapsing remitting multiple sclerosis (RRMS). The treatment in the Ocrelizumab RRMS Phase II study is on-going at this time. The DSMB concluded
Ocrelizumab is also being evaluated for relapsing remitting multiple sclerosis (RRMS). The treatment in the Ocrelizumab RRMS Phase II study is on-going at this time. The DSMB concluded
The company has reported a net loss of $1,433,922, or ($0.11) per share, compared with a net loss of $11,852,152, or ($1.12) per share. Opexa has posted an
NerPharMa manufactures CTI’s drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. CTI has a New Drug Application (NDA)
The study, Horizon III, assessed the efficacy of Cediranib compared with Bevacizumab, both in combination with chemotherapy. Clinical activity was observed in the Cediranib arm of the study
Spray drying is an important technology to improve the bioavailability of poorly soluble APIs. The spray drying technology can be applied in pharmaceutical production to obtain several benefits
Sigma Life Science said that the extension of its product offering, the first ever models created especially for ADME/Tox applications, is expected to help researchers establish the efficacy
The companies have earmarked an estimated total of $1.4bn for the expansion. They have begun the expansion at BYC in September 2009. According to Johnny Kwan, board chairman
SecureTrace is a syndicate of 10 companies in the UK that are using technology to fight counterfeiting and diversion of pharmaceuticals throughout the supply chain. The project, according
According to Neil Ferguson, vice-president of finance with Stirling Products in Charlottetown, Stirling Products of Australia will have control over both the North Sydney plant and the Charlottetown
Cros NT said that Estimate, which has expertise and a particular excellence concerning the oncology and dermatology-related research, would enrich it. Estimate, found in 1992, is a privately